What Do You Want to Know? A Reader's Survey Tells All
Learn what Applied Clinical Trial's readers told us in our annual reader's survey.
What Do You Want to Know? A Reader's Survey Tells AllDid you respond to Applied Clinical Trials' reader survey this year? Well, the results are in and those of you who did respond gave us an inside look into what clinical trials professionals are planning for their businesses in the next year and what they want to learn more about both in print and online.
New strategies that respondent's organizations would be undertaking in the next year to remain competitive included increasing efficiencies with technology (70%) and forming partnerships (58%). The hot topics that people want addressed in the next year are good clinical practice (64%), economic impact on the industry (43%), and eClinical (43%).Delving deeper into article topics, respondents want to see more on regulations, Phase II-III trials, education and training, Phase IV trials/postmarketing, and biotechnology.Check out page 8 to see the lucky respondent who won a flat screen television for participating in Applied Clinical Trials' survey this year.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
STEP UP Trial Shows Semaglutide 7.2 mg Achieves Superior Weight Loss vs. 2.4 mg, Placebo
January 17th 2025Semaglutide 7.2 mg significantly outperformed semaglutide 2.4 mg and placebo with a 20.7% average reduction in weight and a comparable safety and tolerability profile, further establishing its efficacy in obesity treatment.
